Frameshift Portfolio Company Affigen Raises $17 million Series A Led by Black Beret Life Sciences

Funding for Development of Cancer Immunotherapies Targeting Cell Lineage-Specific Tumor Proteins Feb. 21, 2017 (ST. LOUIS and HOUSTON) — Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, today announced the closing of a $17 million Series A financing round led by Black Beret Life Sciences on behalf of its affiliate BBLS […]